Tyrosine News and Research

RSS

Disorderly protein brings order to cell division

The secret to the ability of a molecule critical for cell division to throw off the protein yoke that restrains its activity is the yoke itself - a disorderly molecule that seems to have a mind of its own, say investigators at St. Jude

13 Mar 2007

Cell pathway identified which plays critical role in colon cancer

For the one in 18 men and women who will be diagnosed with cancer of the colon and rectum during their lifetime and over 150,000 people diagnosed on a yearly basis, today's genetic research news offers some optimism.

20 Feb 2007

SH2B1 protein plays a key role in controlling body weight, response to insulin and leptin

A single protein in brain cells may act as a linchpin in the body's weight-regulating system, playing a key role in the flurry of signals that govern fat storage, sugar use, energy balance and weight, University of Michigan Medical School researchers report.

29 Jan 2007

Disorderly protein brings order to cell division

The secret to the ability of a molecule critical for cell division to throw off the protein yoke that restrains its activity is the yoke itself a disorderly molecule that seems to have a mind of its own, say investigators at St. Jude Children's Research Hospital, Innsbruck Medical University and Max Planck Institute.

28 Jan 2007

Gleevec may cause heart problems

Gleevec, the wildly successful poster-child of a new generation of cancer drugs aimed at specific targets in the cancer cell, can be dangerous to the heart.

24 Jul 2006

New molecular target for obesity

Mice bred without the enzyme MKP-1 are resistant to weight gain despite consuming high fat foods and eating more than control mice, according to a research study published online in Cell Metabolism.

24 Jul 2006

Probable cause for Parkinson's found

Parkinson's, Alzheimer's, Lou Gehrig's disease and other brain disorders are among a growing list of maladies attributed to oxidative stress, the cell damage caused during metabolism when the oxygen in the body assumes ever more chemically reactive forms.

28 Jun 2006

Dasatinib offers new options for leukemia patients

Dasatinib, an experimental drug under development by Bristol-Myers Squibb, reverses the signs and symptoms of patients whose chronic myeloid leukemia has failed to respond to Gleevec, which is considered the standard of treatment for the disorder.

14 Jun 2006

Discovery of protein associated with severe preeclampsia

Researchers have identified a second protein which, in combination with sFlt1, escalates preeclampsia to a severe - and life-threatening - state.

6 Jun 2006

Sunitinib malate shows promise against advanced form of lung cancer

Results of a multi-center clinical study of a drug currently approved for treatment of kidney cancer indicate that it may also be effective for people with recurrent and advanced lung cancer.

5 Jun 2006

Cause of neurodegeneration in Huntington's disease discovered

The severe neurodegeneration associated with Huntington's disease may result from molecular mutations that block the transport of nutrients within cells.

1 Jun 2006

Novel animal model of lung adenocarcinoma

Drs. Katerina Politi, Harold Varmus and colleagues at the Memorial Sloan Kettering Cancer Center in New York have developed a novel animal model of lung adenocarcinoma that will be of great use in testing the efficacy of targeted therapies against human lung cancer.

17 May 2006

New treatment for chronic eosinophilic leukemia

Leukemia - or cancer of the bone marrow - strikes some 700 Belgians each year. Chronic Eosinophilic Leukemia (CEL), a specific form of leukemia, is currently treated with Glivec.

10 May 2006

Three-dimensional breast cell cultures reveal clues to breast cancer hidden inside stem cells

Stem cells and how to boost them is hot on the research agenda. But stopping them could be critical too, as evidence implicating stem cells in cancer is mounting.

3 May 2006

Therapy for metastatic renal cell carcinoma remains inadequate

The recent FDA approvals of the tyrosine kinase inhibitors sorafenib and sunitinib based on their activity in metastatic renal cell carcinoma have excited the medical oncology community

9 Mar 2006

New way to study proteins in live cells

For the first time, Johns Hopkins researchers were able to easily jumpstart the activity of a well-known cancer protein in live cells with a small molecule, a strategy that pinpointed key players in the cancer process and can be used to determine new therapeutic targets.

9 Mar 2006

SRY protein explains why men more likely to develop Parkinson's

Scientists at Prince Henry's Institute, Melbourne, and the University of California, Los Angeles, have discovered that SRY, the male protein that forms the testes is also produced in the brain region affected in Parkinson's disease.

24 Feb 2006

Monotherapy phase I clinical trials of novel cytotoxics, targeted therapeutics, antimetastatic agents/angiogenesis inhibitors, and immunotherapeutics/vaccines

Numerous novel oncology agents are currently in phase I monotherapy trials. New Medicine's Oncology KnowledgeBASE (nm|OK) has updated the records of 92 such agents with preclinical or clinical results reported during the 2005 meetings of the American Association for Cancer Research (AACR)

7 Feb 2006

Imatinib mesylate (Gleevec) may not be effective at treating kidney cancer

Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs), is not likely to be effective for patients with high grade renal cell carcinoma -- the most aggressive kidney cancer.

22 Dec 2005

AMN107 drug shows promise in leukemia resistance to Gleevec

The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard therapy for these cancers, say researchers at The University of Texas M. D. Anderson Cancer Center.

13 Dec 2005